Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 5,596,006
  • Shares Outstanding, K 123,970
  • Annual Sales, $ 346,620 K
  • Annual Income, $ -86,560 K
  • 36-Month Beta 2.62
  • Price/Sales 16.01
  • Price/Cash Flow 163.40
  • Price/Book 27.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.05 +13.40%
on 05/15/17
49.50 -5.96%
on 04/25/17
+0.81 (+1.77%)
since 04/24/17
3-Month
37.26 +24.93%
on 04/06/17
56.91 -18.20%
on 03/03/17
+1.96 (+4.40%)
since 02/24/17
52-Week
19.59 +137.62%
on 05/27/16
57.00 -18.33%
on 12/27/16
+13.18 (+39.50%)
since 05/24/16

Most Recent Stories

More News
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 8.15 (-0.61%)
AKBA : 14.24 (+2.08%)
VRTX : 117.80 (+1.04%)
IONS : 46.55 (+3.12%)
REGN : 458.24 (-0.68%)
ALXN : 101.08 (-3.40%)
BIIB : 253.33 (+2.11%)
Ionis (IONS) Stock Falls Despite Positive Inotersen Data

Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

VVUS : 1.10 (-1.79%)
IONS : 46.55 (+3.12%)
MEIP : 1.67 (+1.21%)
GSK : 42.95 (-0.02%)
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

AKTX : 6.51 (-9.21%)
IONS : 46.55 (+3.12%)
BMY : 53.82 (-0.72%)
BIIB : 253.33 (+2.11%)
Today's Research Reports on Stocks to Watch: Ionis Pharmaceuticals and Exact Sciences Corporation

NEW YORK, NY / ACCESSWIRE / May 16, 2017 / Exact Sciences saw a drop on Monday after a Citron Research note had said the company's colon cancer test was a "disastrous business model." It took the company's...

EXAS : 32.96 (+3.32%)
IONS : 46.55 (+3.12%)
Here's Why Shares of Ionis Pharma (IONS) are Falling Today

On Monday, shares of Ionis Pharmaceuticals Inc. (IONS) are falling, down about 10% in morning trading after the company announced results from its 15-month long Phase 3 Neuro-TTR Study of its drug Inotersen...

IONS : 46.55 (+3.12%)
Ionis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 9:20 a.m....

IONS : 46.55 (+3.12%)
Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the appointment of Edward Fitzgerald to the company's board of directors. Mr. Fitzgerald, former...

ARIA : 23.99 (+0.17%)
IONS : 46.55 (+3.12%)
Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 11:30 AM Eastern Time....

IONS : 46.55 (+3.12%)
Ionis Pharmaceuticals (IONS) Beats on Q1 Earnings

Ionis reported earnings of 3 cents including stock based compensation which surpassed the Zacks Consensus Estimate of loss of 4 cents

IONS : 46.55 (+3.12%)
Ionis Reports Financial Results and Highlights for First Quarter 2017

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported significantly improved financial results over the same period last year with operating income of $14 million and net income of $3 million, both...

IONS : 46.55 (+3.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Support & Resistance

2nd Resistance Point 48.68
1st Resistance Point 47.62
Last Price 46.55
1st Support Level 45.10
2nd Support Level 43.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.